Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB007 in Adults and Adolescents With Allergic Asthma
CTR20170959Phase 3Completed
- Sponsor
- Shanghai Zhangjiang Biotech
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, sponsored by Shanghai Zhangjiang Biotech. Started Oct 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on CTR20170959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170959.